Aemetis - AMTX Stock Forecast, Price & News

Aemetis, Inc. operates as a renewable natural gas and renewable fuels company in North America and India. It operates through three segments: California Ethanol, Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the acquisition, development, and commercialization of negative carbon intensity products and technologies that replace traditional petroleum-based products. It sells biodiesel primarily to government oil marketing companies, transport companies, resellers, distributors, and private refiners through its own sales force and independent sales agents, as well as to brokers who resell the product to end-users. The company also produces and sells ethanol; and wet distillers grains, distillers corn oil, and condensed distillers solubles to dairies and feedlots as animal feed. In addition, it produces dairy biogas; produces and sells high-grade alcohol and various feed products, as well as hand sanitizers; and researches and develops conversion technologies using waste feedstocks to produce biofuels and biochemicals. The company was formerly known as AE Biofuels, Inc. and changed its name to Aemetis, Inc. in November 2011. Aemetis, Inc. was founded in 2005 and is headquartered in Cupertino, California.

Aemetis Trading Up 1.5 %

NASDAQ:AMTX opened at $10.66 on Friday. Aemetis has a 1 year low of $4.45 and a 1 year high of $23.33. The company has a fifty day simple moving average of $6.49 and a 200 day simple moving average of $9.09. The company has a market cap of $368.62 million, a P/E ratio of -9.43 and a beta of 0.62.

Aemetis (NASDAQ:AMTX - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The specialty chemicals company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.41. During the same quarter in the prior year, the business posted ($0.38) earnings per share. Equities research analysts forecast that Aemetis will post -1.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AMTX. StockNews.com upgraded shares of Aemetis to a "sell" rating in a research note on Monday. Ascendiant Capital Markets lowered Aemetis to an "outperform" rating and set a $33.00 price target for the company. in a research report on Monday, June 6th. Credit Suisse Group lowered their price target on Aemetis from $35.00 to $27.00 and set an "outperform" rating on the stock in a research report on Monday, June 13th. Finally, Truist Financial cut Aemetis from a "buy" rating to a "hold" rating and set a $12.00 target price on the stock. in a report on Tuesday. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $26.25.